Search results
Results from the WOW.Com Content Network
Meclizine, sold under the brand name Bonine, among others, is an antihistamine used to treat motion sickness and dizziness . [3] It is taken by mouth. [3] Effects generally begin in an hour and last for up to a day. [3] Common side effects include sleepiness and dry mouth. [3] Serious side effects may include allergic reactions. [3]
Acute use (1–3 days) yields a potency about 1.5× stronger than that of morphine and chronic use (7 days+) yields a potency about 2.5 to 5× that of morphine. Similarly, the effect of tramadol increases after consecutive dosing due to the accumulation of its active metabolite and an increase of the oral bioavailability in chronic use.
Teeth discoloration and same side effects as tetracycline. Not to be given to children and pregnant or lactating women. Similar structure with tetracycline, but five times stronger, big volume distribution and long half-time in the body Tinidazole: Tindamax Fasigyn: Protozoal infections: Upset stomach, bitter taste, and itchiness: Trimethoprim(Bs)
Flunarizine is a selective calcium antagonist with moderate other actions including antihistamine, serotonin receptor blocking and dopamine D 2 blocking activity. Compared to other calcium channel blockers such as dihydropyridine derivatives, verapamil and diltiazem, flunarizine has low affinity to voltage-dependent calcium channels.
Dizziness can be brought on by issues inside and outside of the brain. Here are all the possible triggers and what you can do about them, according to a doctor.
Enhances effects of CNS depressants e.g. alcohol, barbiturates, hypnotics, opioid analgesics, anxiolytics and antipsychotics. Can mask signs of ototoxicity caused by aminoglycosides. QT prolongation (which can lead to torsades de pointes arrhythmia) reported with spiramycin.
There are potential long-term side effects of semaglutide. These are rare. They include pancreatitis, acute kidney injury, gallbladder problems, increased heart rate, diabetic retinopathy, mental ...
The study, which was published in Nature Medicine on January 20, analyzed data from more than 2 million people with diabetes who took GLP-1 receptor agonist medications like Ozempic and Wegovy.